|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Shave biopsy and immunohistochemical studies revealed that the tumor was composed of malignant melanoma (MM) (highlighted by S100 and MART-1) intermixed with squamous cell carcinoma (SCC) (highlighted by cytokeratin and p63), and a diagnosis of combined MM-SCC was rendered.
|
31361351 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
|
30520800 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort study evaluated 123 melanomas excised using MMS with MART-1 immunostain.
|
30199430 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, subcutaneous immunization of C57BL/6J mice with DCs ex vivo transfected with an electrostatic complex of AuNPs-SL & melanoma antigen (MART1) encoded DNA vaccine (p-CMV-MART1) induced a long lasting (100 days) anti-tumor immune response in immunized mice upon subsequent challenge with a lethal dose of melanoma.
|
30964937 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The CD44 expression correlated to PD-L1, but not to MART-1 expression in malignant melanoma.
|
31741714 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with melanoma who enrolled in the F5-MART-1 clinical trial (NCT00910650) received infusions of MART-1 T-cell receptors transgenic T cells with MART-1 peptide-pulsed dendritic cell vaccination.
|
29470191 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate using human melanoma cell lines that this resistance phenotype can be induced <i>in vitro</i> by treatment with MART1 T cell receptor-expressing T cells or with TNFα, and that the phenotype is reversible with withdrawal of inflammatory stimuli.
|
29899062 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One paraffin-embedded section of the patients' primary melanoma (n = 60), relapse (n = 21), and naevus (n = 17) were immunohistochemically double-stained for Ki-67/MART1 and single-stained for CD271, CD166, and CD20.
|
29678478 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that SOX10 is more specific than MART-1 in distinguishing epidermal melanocytes on sun-damaged skin by avoiding overdiagnosis of melanoma.
|
29377259 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
|
29933102 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this paper, we propose a technique for measuring melanoma DoI in microscopic images digitized from MART1 (i.e., meleanoma-associated antigen recognized by T cells) stained skin histopathological sections.The technique consists of four modules.
|
28346884 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTL1 promotes melanoma proliferation by regulating Wnt/β-catenin signalling.
|
29285312 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MART1, a human melanoma-specific tumor antigen, was used to induce an increased immune reaction, since a MART1-protective response is required to overcome immune tolerance to the melanoma antigen MelanA.
|
28178658 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NFATc2(+/Hi) melanoma cell lines were CD271(+) and deficient for expression of melanocyte differentiation antigens (MDAs) MART-1, gp100, tyrosinase and of GPNMB, PGC1-α and Rab27a, all regulated by MITF.
|
26387540 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-A2-restricted TCR-transduced (TD) CIK directed against the melanoma antigens Mart1 and NY-ESO1 were generated by lentiviral transduction and successfully expanded over a 3-4-week period.
|
25758764 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, impressive clinical responses were seen in melanoma and synovial cell carcinoma with TCR-modified T cells redirected against the melanocyte lineage antigen MART-1 and the testis-cancer antigen NY-ESO-1.
|
23804078 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TILs transduced with the IL-15 HSV-TK vector retained specific recognition of HLA-A2+, MART1+ melanomas, even after withdrawal of IL-2.
|
23582229 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma antigen recognized by T-cells (MART-1) has been studied extensively as a clinically important diagnostic marker for melanoma, however, its biological function remains unclear.
|
23877836 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This assay is dependent on augmentation of MelanA/MART-1 antigen presentation by a melanoma cell line (MU89).
|
22085019 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
|
21159666 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we evaluated the effect of lovastatin on the proliferation and effector function of the CD8+ tumor-infiltrating lymphocytes (TILs) derived from melanoma patients specific for MART-1 antigen.
|
20948439 |
2011 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Other cells that contain MART-1 mRNA are clearly not melanoma cells or may represent melanoma hybrids.
|
21997686 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation.
|
20547105 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was an increase in melanomaassociated antigen recognized by T cells (MART-1)-specific T cells in tumors undergoing regression after vaccination compared with T cells derived from melanoma patients not treated with vaccine.
|
19915919 |
2010 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CD8(+) T-cells specific for MART-1-(26-35), a dominant melanoma epitope restricted by human leukocyte antigen (HLA)-A*0201, are exceptionally common in the naive T-cell repertoire.
|
19605354 |
2009 |